Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer

Oncogene. 2022 Jun;41(23):3210-3221. doi: 10.1038/s41388-022-02284-z. Epub 2022 May 3.

Abstract

Colorectal cancer (CRC) is the leading cause of cancer associated death worldwide. Ferroptosis is a newly defined form of regulated cell death characterized by the accumulation of lipid hydroperoxides and exerts an increased attention for cancer treatment. However, little is known about ferroptosis in CRC. In this study, through whole genome sequencing and external differential differentiated expression analysis, we identify CUL9 as a novel important modulator for ferroptosis in CRC. Here we demonstrated that CUL9 can binds p53 to ubiquitylate heterogeneous nuclear ribonucleoprotein C for degradation. Overexpression of CUL9 increases resistance to erastin-induced ferroptosis. Then, we discovered this resistance was mediated by CUL9-HNRNPC-MATE1 negative loop, which can provide us with a novel target to overcome drug resistance to ferroptosis activators. Finally, we found that targeting MDM2 was developed as an effective strategy to destroy precious drug-resistant CRC cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • Cullin Proteins / metabolism
  • Ferroptosis* / genetics
  • Heterogeneous-Nuclear Ribonucleoprotein Group C
  • Humans
  • Piperazines
  • Proto-Oncogene Proteins c-mdm2 / genetics
  • Proto-Oncogene Proteins c-mdm2 / metabolism
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Cullin Proteins
  • HNRNPC protein, human
  • Heterogeneous-Nuclear Ribonucleoprotein Group C
  • Piperazines
  • Tumor Suppressor Protein p53
  • erastin
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2